ENTRY       hsa05221                    Pathway
NAME        Acute myeloid leukemia - Homo sapiens (human)
DESCRIPTION Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and accumulation in the bone marrow of blasts with an impaired differentiation program. AML accounts for approximately 80% of all adult leukemias and remains the most common cause of leukemia death. Two major types of genetic events have been described that are crucial for leukemic transformation. A proposed necessary first event is disordered cell growth and upregulation of cell survival genes. The most common of these activating events were observed in the RTK Flt3, in N-Ras and K-Ras, in Kit, and sporadically in other RTKs. Alterations in myeloid transcription factors governing hematopoietic differentiation provide second necessary event for leukemogenesis. Transcription factor fusion proteins such as AML-ETO, PML-RARalpha or PLZF-RARalpha block myeloid cell differentiation by repressing target genes. In other cases, the transcription factors themselves are mutated.
CLASS       Human Diseases; Cancer: specific types
PATHWAY_MAP hsa05221  Acute myeloid leukemia
NETWORK     nt06210  ERK signaling (cancer)
            nt06214  PI3K signaling (cancer)
            nt06219  JAK-STAT signaling (cancer)
            nt06240  Transcription (cancer)
            nt06260  Colorectal cancer
            nt06261  Gastric cancer
            nt06262  Pancreatic cancer
            nt06266  Non-small cell lung cancer
            nt06268  Melanoma
            nt06271  Endometrial cancer
            nt06274  Thyroid cancer
            nt06275  Acute myeloid leukemia
  ELEMENT   N00003  Mutation-activated KIT to RAS-ERK signaling pathway
            N00004  Duplication or mutation-activated FLT3 to RAS-ERK signaling pathway
            N00012  Mutation-activated KRAS/NRAS to ERK signaling pathway
            N00031  Duplication or mutation-activated FLT3 to RAS-PI3K signaling pathway
            N00032  Mutation-activated KRAS/NRAS to PI3K signaling pathway
            N00046  Mutation-activated KIT to PI3K signaling pathway
            N00054  Duplication or mutation-activated FLT3 to Jak-STAT signaling pathway
            N00108  AML1-ETO fusion to transcriptional activtion
            N00109  PML-RARA fusion to transcriptional activtion
            N00110  PLZF-RARA fusion to transcriptional activtion
            N00111  AML1-ETO fusion to CEBPA-mediated transcription
            N00112  AML1-ETO fusion to PU.1-mediated transcription
            N00113  PML-RARA fusion to transcriptional repression
            N00114  PLZF-RARA fusion to transcriptional repression
            N00116  Mutation-inactivated RUNX1 to transcription
DISEASE     H00003  Acute myeloid leukemia
DRUG        D00094  Tretinoin (JAN/USP/INN)
            D05029  Midostaurin (JAN/USAN/INN)
            D10176  Trametinib dimethyl sulfoxide (JAN/USAN)
            D10800  Gilteritinib fumarate (JAN/USAN)
            D12476  Tuspetinib (USAN/INN)
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        10000  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
            1050  CEBPA; CCAAT enhancer binding protein alpha [KO:K09055]
            1053  CEBPE; CCAAT enhancer binding protein epsilon [KO:K10051]
            110117499  P3R3URF-PIK3R3; P3R3URF-PIK3R3 readthrough [KO:K02649]
            11040  PIM2; Pim-2 proto-oncogene, serine/threonine kinase [KO:K08806] [EC:2.7.11.1]
            1147  CHUK; component of inhibitor of nuclear factor kappa B kinase complex [KO:K04467] [EC:2.7.11.10]
            1436  CSF1R; colony stimulating factor 1 receptor [KO:K05090] [EC:2.7.10.1]
            1437  CSF2; colony stimulating factor 2 [KO:K05427]
            1848  DUSP6; dual specificity phosphatase 6 [KO:K21946] [EC:3.1.3.16 3.1.3.48]
            1978  EIF4EBP1; eukaryotic translation initiation factor 4E binding protein 1 [KO:K07205]
            207  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
            208  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
            2209  FCGR1A; Fc gamma receptor Ia [KO:K06498]
            2322  FLT3; fms related receptor tyrosine kinase 3 [KO:K05092] [EC:2.7.10.1]
            2475  MTOR; mechanistic target of rapamycin kinase [KO:K07203] [EC:2.7.11.1]
            2885  GRB2; growth factor receptor bound protein 2 [KO:K04364]
            3265  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
            3551  IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta [KO:K07209] [EC:2.7.11.10]
            3562  IL3; interleukin 3 [KO:K04736]
            3684  ITGAM; integrin subunit alpha M [KO:K06461]
            369  ARAF; A-Raf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1]
            3728  JUP; junction plakoglobin [KO:K10056]
            3815  KIT; KIT proto-oncogene, receptor tyrosine kinase [KO:K05091] [EC:2.7.10.1]
            3845  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
            4353  MPO; myeloperoxidase [KO:K10789] [EC:1.11.2.2]
            4609  MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377]
            4790  NFKB1; nuclear factor kappa B subunit 1 [KO:K02580]
            4893  NRAS; NRAS proto-oncogene, GTPase [KO:K07828]
            51176  LEF1; lymphoid enhancer binding factor 1 [KO:K04492]
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            5292  PIM1; Pim-1 proto-oncogene, serine/threonine kinase [KO:K04702] [EC:2.7.11.1]
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            5295  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            5296  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            5371  PML; PML nuclear body scaffold [KO:K10054] [EC:2.3.2.-]
            5467  PPARD; peroxisome proliferator activated receptor delta [KO:K04504]
            5594  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            5595  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            5604  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            5605  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            572  BAD; BCL2 associated agonist of cell death [KO:K02158]
            5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
            5914  RARA; retinoic acid receptor alpha [KO:K08527]
            595  CCND1; cyclin D1 [KO:K04503]
            597  BCL2A1; BCL2 related protein A1 [KO:K02162]
            5970  RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735]
            6198  RPS6KB1; ribosomal protein S6 kinase B1 [KO:K04688] [EC:2.7.11.1]
            6199  RPS6KB2; ribosomal protein S6 kinase B2 [KO:K04688] [EC:2.7.11.1]
            6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
            6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
            6688  SPI1; Spi-1 proto-oncogene [KO:K09438]
            673  BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1]
            6774  STAT3; signal transducer and activator of transcription 3 [KO:K04692]
            6776  STAT5A; signal transducer and activator of transcription 5A [KO:K11223]
            6777  STAT5B; signal transducer and activator of transcription 5B [KO:K11224]
            6932  TCF7; transcription factor 7 [KO:K02620]
            6934  TCF7L2; transcription factor 7 like 2 [KO:K04491]
            7704  ZBTB16; zinc finger and BTB domain containing 16 [KO:K10055]
            83439  TCF7L1; transcription factor 7 like 1 [KO:K04490]
            8503  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            8517  IKBKG; inhibitor of nuclear factor kappa B kinase regulatory subunit gamma [KO:K07210]
            861  RUNX1; RUNX family transcription factor 1 [KO:K08367]
            862  RUNX1T1; RUNX1 partner transcriptional co-repressor 1 [KO:K10053]
            8864  PER2; period circadian regulator 2 [KO:K02633]
            890  CCNA2; cyclin A2 [KO:K06627]
            8900  CCNA1; cyclin A1 [KO:K06627]
            929  CD14; CD14 molecule [KO:K04391]
COMPOUND    C05981  Phosphatidylinositol-3,4,5-trisphosphate
REFERENCE   PMID:16236521
  AUTHORS   Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H.
  TITLE     The molecular pathogenesis of acute myeloid leukemia.
  JOURNAL   Crit Rev Oncol Hematol 56:195-221 (2005)
            DOI:10.1016/j.critrevonc.2004.10.012
REFERENCE   PMID:12563308
  AUTHORS   Tenen DG.
  TITLE     Disruption of differentiation in human cancer: AML shows the way.
  JOURNAL   Nat Rev Cancer 3:89-101 (2003)
            DOI:10.1038/nrc989
REFERENCE   PMID:16146838
  AUTHORS   Choudhary C, Muller-Tidow C, Berdel WE, Serve H.
  TITLE     Signal transduction of oncogenic Flt3.
  JOURNAL   Int J Hematol 82:93-9 (2005)
            DOI:10.1532/IJH97.05090
REFERENCE   PMID:12951584
  AUTHORS   Stirewalt DL, Radich JP.
  TITLE     The role of FLT3 in haematopoietic malignancies.
  JOURNAL   Nat Rev Cancer 3:650-65 (2003)
            DOI:10.1038/nrc1169
REFERENCE   PMID:16642045
  AUTHORS   Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L.
  TITLE     Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
  JOURNAL   Leukemia 20:911-28 (2006)
            DOI:10.1038/sj.leu.2404245
REFERENCE   PMID:15625120
  AUTHORS   Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R.
  TITLE     Normal and oncogenic forms of the receptor tyrosine kinase kit.
  JOURNAL   Stem Cells 23:16-43 (2005)
            DOI:10.1634/stemcells.2004-0117
REFERENCE   PMID:11721960
  AUTHORS   Lorsbach RB, Downing JR.
  TITLE     The role of the AML1 transcription factor in leukemogenesis.
  JOURNAL   Int J Hematol 74:258-65 (2001)
            DOI:10.1007/BF02982058
REFERENCE   PMID:12468433
  AUTHORS   Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H.
  TITLE     Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
  JOURNAL   Blood 101:3164-73 (2003)
            DOI:10.1182/blood-2002-06-1677
REFERENCE   PMID:16352814
  AUTHORS   Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG.
  TITLE     ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
  JOURNAL   Blood 107:3330-8 (2006)
            DOI:10.1182/blood-2005-07-3068
REFERENCE   PMID:12529654
  AUTHORS   Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C
  TITLE     New mechanisms of AML1 gene alteration in hematological malignancies.
  JOURNAL   Leukemia 17:9-16 (2003)
            DOI:10.1038/sj.leu.2402766
REFERENCE   PMID:12032780
  AUTHORS   Scandura JM, Boccuni P, Cammenga J, Nimer SD
  TITLE     Transcription factor fusions in acute leukemia: variations on a theme.
  JOURNAL   Oncogene 21:3422-44 (2002)
            DOI:10.1038/sj.onc.1205315
REFERENCE   PMID:10717473
  AUTHORS   Lutterbach B, Hiebert SW
  TITLE     Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation.
  JOURNAL   Gene 245:223-35 (2000)
            DOI:10.1016/S0378-1119(00)00014-7
REFERENCE   PMID:19075268
  AUTHORS   Koschmieder S, Halmos B, Levantini E, Tenen DG
  TITLE     Dysregulation of the C/EBPalpha differentiation pathway in human cancer.
  JOURNAL   J Clin Oncol 27:619-28 (2009)
            DOI:10.1200/JCO.2008.17.9812
REFERENCE   PMID:15985538
  AUTHORS   Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP
  TITLE     Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia.
  JOURNAL   Blood 106:2827-36 (2005)
            DOI:10.1182/blood-2005-01-0358
REFERENCE   PMID:12130514
  AUTHORS   Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG
  TITLE     Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
  JOURNAL   Blood 100:998-1007 (2002)
            DOI:10.1182/blood.V100.3.998
REFERENCE   PMID:12393465
  AUTHORS   Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G
  TITLE     The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
  JOURNAL   Blood 101:270-7 (2003)
            DOI:10.1182/blood-2002-04-1288
REFERENCE   PMID:15024077
  AUTHORS   Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Kohler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H
  TITLE     Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
  JOURNAL   Mol Cell Biol 24:2890-904 (2004)
            DOI:10.1128/MCB.24.7.2890-2904.2004
REFERENCE   PMID:11090075
  AUTHORS   Muller C, Yang R, Park DJ, Serve H, Berdel WE, Koeffler HP
  TITLE     The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia.
  JOURNAL   Blood 96:3894-9 (2000)
REFERENCE   PMID:15160934
  AUTHORS   Jing Y
  TITLE     The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
  JOURNAL   Leuk Lymphoma 45:639-48 (2004)
            DOI:10.1080/10428190310001609933
REFERENCE   PMID:11607818
  AUTHORS   Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciari C, Sciurpi MT, Gelmetti V, Riganelli D, Minucci S, Fagioli M, Pelicci PG
  TITLE     Common themes in the pathogenesis of acute myeloid leukemia.
  JOURNAL   Oncogene 20:5680-94 (2001)
            DOI:10.1038/sj.onc.1204642
REFERENCE   PMID:19855079
  AUTHORS   Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI, Leiva M, Ablain J, Ambardekar C, McConnell MJ, Dick JE, Licht JD
  TITLE     Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
  JOURNAL   Blood 114:5499-511 (2009)
            DOI:10.1182/blood-2009-03-206524
REFERENCE   PMID:17554387
  AUTHORS   Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C.
  TITLE     The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.
  JOURNAL   Leukemia 21:1638-47 (2007)
            DOI:10.1038/sj.leu.2404732
REL_PATHWAY hsa04010  MAPK signaling pathway
            hsa04110  Cell cycle
            hsa04150  mTOR signaling pathway
            hsa04151  PI3K-Akt signaling pathway
            hsa04210  Apoptosis
            hsa04630  JAK-STAT signaling pathway
            hsa04640  Hematopoietic cell lineage
KO_PATHWAY  ko05221
///
